Literature DB >> 28482143

Discovery of 1-Hydroxypyridine-2(1H)-thione-6-carboxylic Acid as a First-in-Class Low-Cytotoxic Nanomolar Metallo β-Lactamase Inhibitor.

Woo Shik Shin1, Alexander Bergstrom2, Robert A Bonomo3, Michael W Crowder2, Ramaiah Muthyala4, Yuk Yin Sham1,5.   

Abstract

VIM-2 is one of the most common carbapenem-hydrolyzing metallo β-lactamases (MBL) found in many drug-resistant Gram-negative bacterial strains. Currently, there is a lack of effective lead compounds with optimal therapeutic potential within our drug development pipeline. Here we report the discovery of 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid (3) as a first-in-class metallo β-lactamase inhibitor (MBLi) with a potent inhibition Ki of 13 nm against VIM-2 that corresponds to a remarkable 0.99 ligand efficiency. We further established that 3 can restore the antibiotic activity of amoxicillin against VIM-2-producing E. coli in a whole cell assay with an EC50 of 110 nm. The potential mode of binding of 3 from molecular modeling provided structural insights that could corroborate the observed changes in the biochemical activities. Finally, 3 possesses a low cytotoxicity (CC50 ) of 97 μm with a corresponding therapeutic index of 880, making it a promising lead candidate for further optimization in combination antibacterial therapy.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  1-hydroxypyridine-2(1H)-thiones; VIM-2; drug resistance; metallo β-lactamase; pyrithiones; β-lactam antibiotics

Mesh:

Substances:

Year:  2017        PMID: 28482143      PMCID: PMC6034706          DOI: 10.1002/cmdc.201700182

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  17 in total

Review 1.  The design of inhibitors for medicinally relevant metalloproteins.

Authors:  Faith E Jacobsen; Jana A Lewis; Seth M Cohen
Journal:  ChemMedChem       Date:  2007-02       Impact factor: 3.466

2.  Cell permeable vanX inhibitors as vancomycin re-sensitizing agents.

Authors:  Ramaiah Muthyala; Namrata Rastogi; Woo Shik Shin; Marnie L Peterson; Yuk Yin Sham
Journal:  Bioorg Med Chem Lett       Date:  2014-04-08       Impact factor: 2.823

3.  Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.

Authors:  M Tailler; L Senovilla; E Lainey; S Thépot; D Métivier; M Sébert; V Baud; K Billot; P Fenaux; L Galluzzi; S Boehrer; G Kroemer; O Kepp
Journal:  Oncogene       Date:  2011-11-21       Impact factor: 9.867

4.  Stability and in vitro absorption of captopril, enalapril and lisinopril across the rat intestine.

Authors:  X H Zhou; A Li Wan Po
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

Review 5.  Metallo-β-lactamase structure and function.

Authors:  Timothy Palzkill
Journal:  Ann N Y Acad Sci       Date:  2012-11-16       Impact factor: 5.691

6.  Novel antifouling agent-zinc pyrithione: stress induction and genotoxicity to the marine mussel Mytilus galloprovincialis.

Authors:  Marco Marcheselli; Paola Azzoni; Marina Mauri
Journal:  Aquat Toxicol       Date:  2010-12-29       Impact factor: 4.964

7.  Coordination geometries of metal ions in d- or l-captopril-inhibited metallo-beta-lactamases.

Authors:  Uwe Heinz; Rogert Bauer; Sandra Wommer; Wolfram Meyer-Klaucke; Cyril Papamichaels; John Bateson; Hans-Werner Adolph
Journal:  J Biol Chem       Date:  2003-03-31       Impact factor: 5.157

8.  Zinc ionophores pyrithione inhibits herpes simplex virus replication through interfering with proteasome function and NF-κB activation.

Authors:  Min Qiu; Yu Chen; Ying Chu; Siwei Song; Na Yang; Jie Gao; Zhiwei Wu
Journal:  Antiviral Res       Date:  2013-07-15       Impact factor: 5.970

9.  Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.

Authors:  Ramaiah Muthyala; Woo Shik Shin; Jiashu Xie; Yuk Yin Sham
Journal:  Bioorg Med Chem Lett       Date:  2015-07-26       Impact factor: 2.823

10.  Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers.

Authors:  Jürgen Brem; Sander S van Berkel; David Zollman; Sook Y Lee; Opher Gileadi; Peter J McHugh; Timothy R Walsh; Michael A McDonough; Christopher J Schofield
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

View more
  5 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 2.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

3.  Virtual Screening and Experimental Testing of B1 Metallo-β-lactamase Inhibitors.

Authors:  Joon S Kang; Antonia L Zhang; Mohammad Faheem; Charles J Zhang; Ni Ai; John D Buynak; William J Welsh; Peter Oelschlaeger
Journal:  J Chem Inf Model       Date:  2018-08-29       Impact factor: 4.956

4.  Thiol-Containing Metallo-β-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.

Authors:  Kamaleddin Haj Mohammad Ebrahim Tehrani; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2017-08-28       Impact factor: 5.084

5.  Mechanistic Investigations of Metallo-β-lactamase Inhibitors: Strong Zinc Binding Is Not Required for Potent Enzyme Inhibition*.

Authors:  Nicola Wade; Kamaleddin H M E Tehrani; Nora C Brüchle; Matthijs J van Haren; Vida Mashayekhi; Nathaniel I Martin
Journal:  ChemMedChem       Date:  2021-03-03       Impact factor: 3.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.